Literature DB >> 15582223

Metabotropic glutamate receptors and striatal synaptic plasticity: implications for neurological diseases.

Paolo Gubellini1, Antonio Pisani, Diego Centonze, Giorgio Bernardi, Paolo Calabresi.   

Abstract

Long- and short-term changes in the efficacy of synaptic transmission are known as synaptic plasticity. Phenomena such as long-term depression (LTD) and long-term potentiation (LTP) are two classical forms of synaptic plasticity that are expressed in several brain areas, including the striatum. Bi-directional changes in corticostriatal synaptic transmission, i.e. LTD and LTP, have been proposed to represent the cellular mechanisms underlying the physiological processes of motor learning and behavior. In parallel, other forms of synaptic plasticity induced by different experimental pathological conditions have been described in the striatum; these changes are presumed to represent the cellular processes underlying several neurological disorders, including Parkinson's disease and Huntington's chorea. A considerable number of receptor and post-receptor systems participate in the mechanisms of synaptic plasticity in the striatum, where glutamate plays a primary role through its ionotropic and metabotropic receptors (mGluRs). These latter constitute a group of recently characterized molecules, which have been shown to modulate synaptic transmission by acting on cellular excitability, ionic conductances and neurotransmitter release. These receptors have also been involved in several neuronal pathophysiological processes. The role of mGluRs in synaptic transmission and synaptic plasticity has been recently deeply studied and characterized in the striatum, in both physiological and pathological conditions. These findings open new and interesting perspectives in the study of basal ganglia function, and introduce new possible pharmacological approaches for the treatment of neurological disorders in which mGluRs have been experimentally involved.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15582223     DOI: 10.1016/j.pneurobio.2004.09.005

Source DB:  PubMed          Journal:  Prog Neurobiol        ISSN: 0301-0082            Impact factor:   11.685


  40 in total

1.  Group I mGluRs and long-term depression: potential roles in addiction?

Authors:  Brad A Grueter; Zoé A McElligott; Danny G Winder
Journal:  Mol Neurobiol       Date:  2007-07-27       Impact factor: 5.590

2.  Effect of the metabotropic glutamate antagonist MPEP on striatal expression of the Homer family proteins in levodopa-treated hemiparkinsonian rats.

Authors:  Anna Jiménez; Merce Bonastre; Esther Aguilar; Concepcio Marin
Journal:  Psychopharmacology (Berl)       Date:  2009-07-28       Impact factor: 4.530

3.  Enhanced binding of metabotropic glutamate receptor type 5 (mGluR5) PET tracers in the brain of parkinsonian primates.

Authors:  R Sanchez-Pernaute; J-Q Wang; D Kuruppu; L Cao; W Tueckmantel; A Kozikowski; O Isacson; A-L Brownell
Journal:  Neuroimage       Date:  2008-04-20       Impact factor: 6.556

4.  Metabotropic glutamate mGluR5 receptor blockade opposes abnormal involuntary movements and the increases in glutamic acid decarboxylase mRNA levels induced by l-DOPA in striatal neurons of 6-hydroxydopamine-lesioned rats.

Authors:  N Yamamoto; J-J Soghomonian
Journal:  Neuroscience       Date:  2009-08-04       Impact factor: 3.590

5.  Cocaine and Amphetamine Induce Overlapping but Distinct Patterns of AMPAR Plasticity in Nucleus Accumbens Medium Spiny Neurons.

Authors:  Jakub Jedynak; Matthew Hearing; Anna Ingebretson; Stephanie R Ebner; Matthew Kelly; Rachel A Fischer; Saïd Kourrich; Mark J Thomas
Journal:  Neuropsychopharmacology       Date:  2015-06-12       Impact factor: 7.853

Review 6.  Neurotransmitter receptors and cognitive dysfunction in Alzheimer's disease and Parkinson's disease.

Authors:  Yunqi Xu; Junqiang Yan; Peng Zhou; Jiejie Li; Huimin Gao; Ying Xia; Qing Wang
Journal:  Prog Neurobiol       Date:  2012-02-25       Impact factor: 11.685

Review 7.  Glutamate transporters in the biology of malignant gliomas.

Authors:  Stephanie M Robert; Harald Sontheimer
Journal:  Cell Mol Life Sci       Date:  2013-11-27       Impact factor: 9.261

8.  Therapeutic potential of targeting metabotropic glutamate receptors for Parkinson's disease.

Authors:  Jonathan W Dickerson; P Jeffrey Conn
Journal:  Neurodegener Dis Manag       Date:  2012-04-01

9.  Pharmacological modulation of glutamate transmission in a rat model of L-DOPA-induced dyskinesia: effects on motor behavior and striatal nuclear signaling.

Authors:  Daniella Rylander; Alessandra Recchia; Flora Mela; Andrzej Dekundy; Wojciech Danysz; M Angela Cenci
Journal:  J Pharmacol Exp Ther       Date:  2009-04-08       Impact factor: 4.030

10.  Investigation on tolerance development to subchronic blockade of mGluR5 in models of learning, anxiety, and levodopa-induced dyskinesia in rats.

Authors:  Andreas Gravius; Andrzej Dekundy; Jens Nagel; Lorenzo Morè; Małgorzata Pietraszek; Wojciech Danysz
Journal:  J Neural Transm (Vienna)       Date:  2008-08-09       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.